| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 2 | |||
| NCT04879121 | Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or… | Locally Advanced Malignant Solid Neoplasm | Recruiting |
| NCT06563999 | Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare… | Lung Cancer Stage III | Recruiting |
| NCT06390852 | Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes… | Advanced Lymphoma | Active, Not Recruiting |
| NCT03155620 | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed… | Advanced Malignant Solid Neoplasm | Active, Not Recruiting |
| NCT03213704 | Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors… | Advanced Malignant Solid Neoplasm | Active, Not Recruiting |
| NCT02465060 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced… | Advanced Lymphoma | Active, Not Recruiting |
| Early Phase 1 | |||
| NCT04655404 | A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion | High Grade Glioma | Recruiting |
| Not specified | |||
| NCT04142437 | Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During… | Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion | Recruiting |
| NCT04945330 | NTRK Gene Fusion - Positive Advanced or Recurrent Solid Tumors, a Rare Cancer Caused by… | Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion | Recruiting |